CHEK2 and neoplasm: CHEK2 (Checkpoint Kinase 2) encodes a DDR kinase (CHK2); its loss can raise tumor mutational burden and activate cGAS–STING, while high CHEK2 expression has been linked to weaker benefit from immune checkpoint inhibitors.